Journal article

Real-life data for first-line combination immune- checkpoint inhibition and targeted therapy in patients with melanoma brain metastases

Marie-Luise Hilbers, Florentia Dimitriou, Peter Lau, Prachi Bhave, Grant A McArthur, Lisa Zimmer, Ken Kudura, Camille L Gerard, Mitchell P Levesque, Olivier Michielin, Reinhard Dummer, Phil F Cheng, Joanna Mangana

EUROPEAN JOURNAL OF CANCER | ELSEVIER SCI LTD | Published : 2021

Abstract

BACKGROUND: Melanoma brain metastases (MBM) have a poor prognosis. Systemic treatments that have improved outcomes in advanced melanoma have been shown to have an intracranial (IC) effect. We studied the efficacy and outcomes of combined immune checkpoint inhibitor ipilimumab/nivolumab (Combi-ICI) or targeted therapy (Combi-TT) as first-line treatment in MBM. METHODS: MBM patients treated with Combi-ICI or Combi-TT within 3 months after MBM diagnosis. Endpoints were progression-free survival (PFS) and overall survival (OS). RESULTS: 53 patients received Combi-ICI, 32% had symptomatic MBM and 33.9% elevated LDH. 71.7% required local treatment. The disease control rate was 60.3%. IC response r..

View full abstract

University of Melbourne Researchers